Madison, WINCT06598800Now EnrollingIRB Ready

Advanced Solid Tumor Clinical Trial in Madison, WI

Access cutting-edge advanced solid tumor treatment through this clinical trial at a research site in Madison. Study-provided care at no cost to qualified participants.

Sponsored by BeOne Medicines

Quick Self-Assessment

See if you qualify for this Madison location

Preparing your pre-screening questions…

Expert Care in Madison

Access advanced solid tumor specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related advanced solid tumor treatment provided free

Apply for This Madison Location

Check if you qualify for this advanced solid tumor clinical trial in Madison, WI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Madison

    Convenient for WI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Madison site if eligible
  4. 4Begin participation

About This Advanced Solid Tumor Study in Madison

This is a first-in-human (FIH), Phase 1a/1b, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-T187 alone and in combination with other therapeutic agents in participants with advanced solid tumors.

Sponsor: BeOne Medicines

Who Can Participate

Inclusion Criteria

Able to provide a signed and dated written informed consent prior to any study-specific procedures, sampling, or data collection.
Participants must be ≥ 18 years of age or the legal age of consent in the jurisdiction in which the study is taking place.
Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1.
Participants with selected histologically or cytologically confirmed advanced, metastatic, and unresectable solid tumors who have been previously treated, including but not limited to non-small cell lung cancer (NSCLC), colorectal cancer (CRC).
≥ 1 measurable or nonmeasurable lesion as assessed by RECIST v1.1. for Phase 1a Part A; ≥ 1 measurable lesion per RECIST v1.1. for Phase 1a Part B and Phase 1b.
Adequate organ function.

Exclusion Criteria

Prior severe allergic reactions or hypersensitivity to the active ingredient and excipients of BG-T187 or other monoclonal antibodies.
Spinal cord compression, active leptomeningeal disease, or uncontrolled, untreated brain metastasis.
Any malignancy ≤ 3 years before the first dose of study drug(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast).
History of interstitial lung disease (ILD) or noninfectious pneumonitis requiring steroids or other immune suppressive agents ≤ 2 years before the first dose of the study drug, or with current ILD/noninfectious pneumonitis, or where suspected ILD/noninfectious pneumonitis cannot be ruled out by imaging during screening.
Uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage (recurrence ≤14 days after intervention).
Active hepatitis C.
Infection (including tuberculosis infection, or other) requiring systemic (oral or intravenous) antibacterial, antifungal, or antiviral therapy ≤ 14 days before the first dose of study drug(s). Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Madison?

Yes, this clinical trial (NCT06598800) has an active research site in Madison, WI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Advanced Solid Tumor Treatment Options in Madison, WI

If you're searching for advanced solid tumor treatment options in Madison, WI, this clinical trial (NCT06598800) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Madison research site is actively enrolling participants for this clinical trial. You'll receive care from experienced advanced solid tumor specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all advanced solid tumor clinical trials near you to find additional studies recruiting in your area.

More Advanced Solid Tumors Trials in Madison, WI

See all advanced solid tumors clinical trials recruiting in Madison — not just this study.

Browse Advanced Solid Tumors Trials in Madison

Ready to Join in Madison?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Madison, WI